We are live on ! Find out more
CCP

Clough Capital Partners Portfolio holdings

AUM $1.23B
1-Year Est. Return 51.32%
This Fund
S&P 500
This Quarter Est. Return
+7.68%
1 Year Est. Return
+51.32%
3 Year Est. Return
+175.14%
5 Year Est. Return
+243.7%
10 Year Est. Return
+1,533.05%
AUM
$2.79B
AUM Growth
+$120M
Cap. Flow
-$64.8M
Cap. Flow %
-2.32%
Top 10 Hldgs %
23.33%
Holding
244
New
63
Increased
42
Reduced
62
Closed
70

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 24.97%
2 Healthcare 22.62%
3 Financials 19%
4 Technology 10.74%
5 Communication Services 7.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VCYT icon
101
Veracyte
VCYT
$3.23B
$9.82M 0.35%
1,016,878
+193,188
+23% +$1.51M
AAPL icon
102
Apple
AAPL
$4.84T
$9.57M 0.34%
346,800
+163,600
+89% +$4.45M
LGF
103
DELISTED
Lions Gate Entertainment
LGF
$8.87M 0.32%
276,971
-11,429
-4% -$373K
CRM icon
104
Salesforce
CRM
$210B
$8.82M 0.32%
+148,800
New +$8.77M
NILE
105
DELISTED
Blue Nile, Inc.
NILE
$8.54M 0.31%
237,031
+28,531
+14% +$944K
LBRDA
106
DELISTED
Liberty Broadband Class A
LBRDA
$8.35M 0.3%
+166,618
New +$8.23M
GNW icon
107
Genworth Financial
GNW
$3.78B
$8.07M 0.29%
949,579
-1,069,912
-53% -$11.2M
UAM
108
DELISTED
Universal American Corp
UAM
$7.47M 0.27%
805,273
-299,846
-27% -$2.61M
EFII
109
DELISTED
Electronics for Imaging
EFII
$7.46M 0.27%
174,200
+39,400
+29% +$1.72M
GOOG icon
110
Alphabet (Google) Class C
GOOG
$4.18T
$7.25M 0.26%
276,016
-1,481,556
-84% -$39.8M
TDG icon
111
TransDigm Group
TDG
$60B
$6.94M 0.25%
+35,360
New +$6.67M
PBYI icon
112
Puma Biotechnology
PBYI
$477M
$6.89M 0.25%
+36,400
New +$8.08M
AZN icon
113
CALL
AstraZeneca
AZN
$251B
$6.88M 0.25%
97,700
-48,300
-33% -$3.46M
PBH icon
114
Prestige Consumer Healthcare
PBH
$2.21B
$6.8M 0.24%
195,841
-144,222
-42% -$4.79M
IEMG icon
115
iShares Core MSCI Emerging Markets ETF
IEMG
$158B
$6.63M 0.24%
+140,991
New +$6.88M
ROL icon
116
Rollins
ROL
$16.2B
$6.59M 0.24%
672,118
-48,107
-7% -$449K
GWPH
117
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.73M 0.21%
84,600
-108,000
-56% -$7.89M
AEGR
118
DELISTED
Aegerion Pharmaceuticals
AEGR
$5.55M 0.2%
265,300
-97,800
-27% -$2.46M
KATE
119
DELISTED
Kate Spade & Company
KATE
$5.53M 0.2%
172,796
+13,995
+9% +$399K
SLXP
120
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$5.51M 0.2%
47,900
+24,220
+102% +$2.93M
AX icon
121
Axos Financial
AX
$5.26B
$5.07M 0.18%
+260,800
New +$4.89M
DERM
122
DELISTED
Dermira, Inc.
DERM
$5.03M 0.18%
+277,700
New +$4.64M
AMC icon
123
AMC Entertainment Holdings
AMC
$2.28B
$4.96M 0.18%
18,940
+5,410
+40% +$1.34M
CNC icon
124
Centene
CNC
$33.4B
$4.93M 0.18%
189,956
-196,016
-51% -$4.57M
CORV
125
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$4.74M 0.17%
512,533
+13,529
+3% +$114K

Similar funds

Clough Capital Partners's Q4 2014 Portfolio in Review

As of Q4 2014, Clough Capital Partners held 244 positions worth $2.79B, up 4.5% from $2.67B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Clough Capital Partners's Q4 2014 filing shows 63 new, 42 increased, 62 reduced and 70 closed positions. Its largest new stake was Armstrong World Industries: 820,700 shares worth $42M. The largest sale was Alphabet (Google) Class C, an estimated $39.8M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.

  • Clough Capital Partners's largest Q4 2014 buy was Armstrong World Industries: 820,700 shares worth $42M.
  • Clough Capital Partners added most to Perrigo in Q4 2014, an estimated $22M increase.
  • Clough Capital Partners's biggest Q4 2014 reduction was Alphabet (Google) Class C, cutting an estimated $39.8M.
  • Clough Capital Partners fully exited Charter Communications in Q4 2014, selling an estimated $35.2M.
  • Clough Capital Partners's ten largest holdings make up 23% of its $2.79B portfolio in Q4 2014.
  • Clough Capital Partners opened 63 new positions and closed 70 in Q4 2014.
  • Clough Capital Partners's portfolio value rose 4.5% quarter-over-quarter to $2.79B.

Based on Clough Capital Partners's 13F filing for Q4 2014, filed 17 Feb 2015.